Viking Therapeutics, Inc. Aktie News

GLP-1 market growth is fueling Viking Therapeutics‘ (VKTX) momentum with VK2735 in Phase 3 and VK2809's NASH success. Viking is advancing dual therapies amid a $150 billion obesity opportunity.

Viking Therapeutics is developing a weight loss medicine in the same general class as Eli Lilly's tirzepatide. The mid-cap biotech is exploring options for a potential quadruple agonist therapy.

Viking Therapeutics aims to enter one of today's biggest healthcare growth areas: the weight loss drug market. The company is evaluating an injectable candidate in phase 3 studies and an oral candidate in phase 2.

Viking Therapeutics, Cava Group, and Figma are three stocks that have been struggling in recent months. These businesses possess some exciting growth potential, which could make them ideal long-term investments.

The image featured for this article is © Ground Picture / Shutterstock.com

Poster Presentation on VENTURE Study Results Evaluating Impact of VK2735 on Prediabetes and Cardiometabolic Status Additional Poster Presentations Scheduled for American Heart Association Scientific Sessions 2025 SAN DIEGO , Oct. 29, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies ...

Viking Therapeutics Inc. NASDAQ: VKTX stock is soaring after the company delivered its third-quarter earnings report. The clinical-stage biopharmaceutical company is not profitable and is not generating revenue.

The company's lead drug candidate is in a phase 3 trial, and enrollment is progressing well. The drug is also being tested in oral formulation, and there's plenty of value in Viking's pipeline.